Phio Pharmaceuticals Corp. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Phio Pharmaceuticals (market cap ~$11.2M) reported Q2 2026 results showing cash of $13.0M (down from $21.0M at Dec 31, 2025) with runway into H2 2027. Lead program PH-762 completed 22-patient Phase 1b trial (cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma); company initiated commercial-scale API manufacturing and long-term non-clinical toxicology studies (both expected completed by year-end), received three patent allowances and one grant, and appointed dermatologist Dr. R. Todd Plott to board. R&D expenses surged 187% YoY to $3.1M in Q2 2026 (driven by $0.9M nonclinical toxicology and $1.5M CMC costs); net loss was $4.1M in Q2 2026 vs. $2.2M in Q2 2025. Company established $6.36M ATM equity offering in April 2026 via H.C. Wainwright.
Why this rating
Clinical progress (Phase 1b completion, regulatory pathway prep) and IP fortification are meaningful for pipeline; cash burn rate of ~$4.1M/quarter against $13M balance creates 12-month runway, requiring capital raise—moderate near-term risk. Material relative to $11M market cap.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.